Pulmatrix 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Peter Ludlum

최고 경영자

US$510.2k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4.7yrs

최근 관리 업데이트

Recent updates

CEO

Peter Ludlum (69 yo)

less than a year

테뉴어

US$510,224

보상

Mr. Peter B. Ludlum, CMA, MBA, served as Interim Chief Financial Officer and Principal accounting & financial officer at Pulmatrix, Inc. since April 18, 2022 until July 20, 2024 and also serves as its Inte...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Higgins	Independent Chairman	9.4yrs	US$92.97k	0% € 0
David Denning	Member of Pulmazole Clinical Advisory Board	no data	데이터 없음	데이터 없음
Christopher Cabell	Independent Director	4.4yrs	US$50.56k	0% € 0
Jonathan Corren	Member of Pulmazole Clinical Advisory Board	no data	데이터 없음	데이터 없음
Richard Batycky	Independent Director	5yrs	US$59.56k	0.00068% € 145.7
Todd Bazemore	Independent Director	4.1yrs	US$58.06k	0% € 0
Ritesh Agarwal	Member of Pulmazole Clinical Advisory Board	no data	데이터 없음	데이터 없음
Cendrine Godet	Member of Pulmazole Clinical Advisory Board	no data	데이터 없음	데이터 없음
David Stevens	Member of Pulmazole Clinical Advisory Board	no data	데이터 없음	데이터 없음
Michael Wechsler	Member of Pulmazole Clinical Advisory Board	no data	데이터 없음	데이터 없음
William Calhoun	Chair of PUR1900 & PUR1800 Clinical Advisory Board	no data	데이터 없음	데이터 없음
Stephen Silberstein	Chair of PUR3100 (DHE) Clinical Advisory Board	no data	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

55.5yo

평균 연령

경험이 풍부한 이사회: 2PU 의 이사회는 경험(평균 재직 기간 4.7 년)으로 간주됩니다.

Pulmatrix 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Insufficient new directors

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Recent updates

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

New major risk - Share price stability

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Second quarter 2024 earnings released: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine (PUR3100)

First quarter 2024 earnings released: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

New minor risk - Share price stability

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Second quarter 2023 earnings released: US$1.05 loss per share (vs US$1.36 loss in 2Q 2022)

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings released: US$5.46 loss per share (vs US$8.63 loss in FY 2021)

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings released: US$1.45 loss per share (vs US$2.91 loss in 3Q 2021)

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$1.37 loss in 2Q 2021)

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

First quarter 2022 earnings released: US$1.51 loss per share (vs US$1.78 loss in 1Q 2021)

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

No longer forecast to breakeven

Full year 2021 earnings released: US$8.63 loss per share (vs US$13.43 loss in FY 2020)

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

New 90-day high: €1.41

New 90-day high: €1.17

New 90-day high: €1.15

Revenue in line with expectations

Third quarter 2020 earnings released: US$0.31 loss per share

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령